arimadex

images (1)

Arimadex exhibits higher activity against compared to activity against factor IIa. He has both immediate and prolonged antithrombotic activity.
Compared with unfractionated heparin, nadroparin has less effect on platelet function and aggregation and has little pronounced effect on primary hemostasis.
In prophylactic doses does not cause pronounced reduction of activated partial thrombin.
in exchange treatment in the period of maximum activity of the  may be extended to a value of 1.4 times the standard. This extension reflects the residual antithrombotic effect of nadroparin calcium.

Pharmacokinetics
The pharmacokinetic properties are determined on the basis of changes in anti-Xa-factor activity of plasma. Absorption After subcutaneous administration, maximum is achieved after 35 hours (T max ). The bioavailability after subcutaneous administration of nadroparin almost completely absorbed (about 88%) . When administered intravenously, the maximum  activity is achieved in less than 10 minutes and elimination half-life (T ½ ) is about 2 hours. Metabolism metabolism occurs primarily in the liver (desulfation, depolymerization). Elimination half-life after subcutaneous administration is about 3, 5 hours. However, the anti-Xa activity is maintained for at least 18 hours after injection in a dose of nadroparin arimadex 1,900 .

 

risk groups

Elderly patients
In elderly patients, due to a possible decrease in kidney function, the elimination of nadroparin may slow down. Possible renal insufficiency in these patients require evaluation and appropriate dose adjustment.

Patients with impaired renal function
In clinical trials, that examine the pharmacokinetics of nadroparin administered intravenously in patients with renal failure of varying severity, there was a correlation between nadroparin clearance and creatinine clearance. When compared with the values obtained in healthy volunteers, it was found that the arimadex were increased to 52-87%, and creatinine clearance up to 47-64% of normal values. The study also observed large individual differences. In patients with severe renal failure half-life when administered subcutaneously nadroparin increased to 6 hours. The results showed that a small accumulation of nadroparin may occur in patients with mild or moderate renal impairment (creatinine clearance greater than or equal and less than 60 ml / min), therefore, the dose Fraksiparina should be reduced by 25% in those patients receiving Fraksiparin for the treatment of thromboembolism, unstable angina / myocardial infarction without .